Clinical Trial Update: Expanded Access for Idelalisib in Combination With Rituximab in Chronic Lymphocytic Leukemia

View source ↗

Summary

Expanded-access program launched for idelalisib in combination with rituximab to treat chronic lymphocytic leukemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• Rituxan (rituximab)
• Zydelig (idelalisib)

Snippet

Sponsor: Gilead Sciences | Conditions: Chronic Lymphocytic Leukemia (CLL) | Status: APPROVED_FOR_MARKETING